Core Viewpoint - The announcement indicates that the company's subsidiary, Yanji Pharmaceutical, has received approval for the "Naloxone Hydrochloride Injection" from the National Medical Products Administration, which is expected to enhance market competitiveness and expand market share, although it is not anticipated to have a significant short-term impact on the company's performance [1] Summary by Relevant Categories Product Approval - Yanji Pharmaceutical has received the approval notice for "Naloxone Hydrochloride Injection" with a specification of 1ml: 0.4mg, under the original drug approval number Guoyao Zhunzi H20066188 [1] Market Impact - The approval allows the product to pass the consistency evaluation of quality and efficacy for generic drugs, which is beneficial for increasing the product's market share and competitiveness [1] - It is expected that there will be no significant impact on the company's performance in the short term [1]

Core Viewpoint - Jilin Aodong (000623.SZ) announced that its subsidiary, Yanji Pharmaceutical Group, received approval from the National Medical Products Administration for the "Naloxone Hydrochloride Injection" [1] Group 1: Product Approval - The approval is for Naloxone Hydrochloride Injection, which is an opioid receptor antagonist [1] - Indications for use include: 1. Reversal of respiratory depression caused by opioid drugs after combined anesthesia [1] 2. Complete or partial reversal of respiratory depression due to opioid overdose [1] 3. Rescue in cases of acute ethanol poisoning [1] 4. Diagnosis of acute opioid overdose [1]

药品通用名称：盐酸纳洛酮注射液 英文名/拉丁名：Naloxone Hydrochloride Injection 证券代码:000623 证券简称:吉林敖东 公告编号:2025-055 吉林敖东药业集团股份有限公司 关于控股子公司获得药品补充申请批准通知书 的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，吉林敖东药业集团股份有限公司（以下简称"公司"）控股子公司吉 林敖东药业集团延吉股份有限公司（以下简称"延吉药业"）收到国家药品监督 管理局下发的"盐酸纳洛酮注射液"的《药品补充申请批准通知书》。现就相关 情况公告如下： 一、《药品补充申请批准通知书》的主要内容 剂型：注射剂 注册分类：化学药品 规格：1ml：0.4mg 原药品批准文号：国药准字H20066188 包装规格：10支/盒 药品注册标准编号：YBH27412025 受理号：CYHB2450472 通知书编号：2025B04770 上市许可持有人名称：吉林敖东药业集团延吉股份有限公司 上市许可持有人地址：吉林省延吉市高新技术开发区长白路389号 生产企业名称：吉林敖东药业 ...

Core Viewpoint - The announcement of a 761 million yuan interim dividend by GF Securities highlights the increasing shareholder return awareness within the brokerage industry, reflecting a broader trend among listed brokerages in China to enhance shareholder returns [2][3][7]. Group 1: Dividend Announcement - GF Securities has announced a cash dividend of 761 million yuan, with a record date of October 21 and payment date of October 22, distributing 1 yuan per 10 shares to shareholders [3]. - The total dividend represents 11.76% of the net profit attributable to the parent company for the first half of 2025 [3]. - The company has a total share capital of 7.606 billion shares, with 5.904 billion A-shares and 1.702 billion H-shares, necessitating different dividend distributions for A and H shareholders [3]. Group 2: Shareholder Structure - The three largest shareholders of GF Securities, Jilin Aodong, Liaoning Chengda, and Zhongshan Public Utilities, hold a combined 48% of the company's shares, benefiting significantly from the dividend [4][6]. - Jilin Aodong, the largest shareholder, has stated that GF Securities is a core asset, rejecting suggestions to reduce its stake [4][6]. Group 3: Industry Trends - A total of 28 out of 43 listed brokerages in A-shares have announced interim dividend plans for 2025, with a combined payout of approximately 18.8 billion yuan, marking a year-on-year increase of over 40% [2][7]. - Major brokerages such as CITIC Securities and Guotai Junan are leading in dividend payouts, with CITIC Securities proposing a dividend of 4.298 billion yuan [7]. - The introduction of new participants in the interim dividend scheme, including Shanxi Securities and Huaxi Securities, indicates a growing trend of dividend distribution among brokerages [7][8]. Group 4: Dividend Quality - The dividend payout ratio, a key indicator of dividend quality, has garnered attention, with six brokerages reporting ratios exceeding 30% [8]. - Dongwu Securities plans to increase its minimum annual cash distribution from 30% to 50% of distributable profits over the next three years, enhancing its commitment to shareholder returns [8].

Market Overview - The Chinese traditional medicine sector rose by 0.84% on October 15, with Zhendong Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] Stock Performance - Zhendong Pharmaceutical (300158) closed at 6.93, with a gain of 5.64% and a trading volume of 913,500 shares, amounting to a transaction value of 636 million yuan [1] - Tianmu Pharmaceutical (600671) closed at 19.62, up 5.31%, with a trading volume of 73,800 shares [1] - Zuoli Pharmaceutical (300181) closed at 19.07, increasing by 4.21%, with a trading volume of 283,300 shares [1] - Other notable performers include Zhongsheng Pharmaceutical (002317) and Xintian Pharmaceutical (002873), with gains of 3.99% and 3.70% respectively [1] Capital Flow - The traditional medicine sector saw a net inflow of 378 million yuan from institutional investors, while retail investors experienced a net outflow of 276 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors showing confidence while retail investors withdrew funds [2] Individual Stock Capital Flow - Zuoli Pharmaceutical (300181) had a net inflow of 76.71 million yuan from institutional investors, while retail investors saw a net outflow of 38.14 million yuan [3] - Zhendong Pharmaceutical (300158) experienced a net inflow of 56.45 million yuan from institutional investors, with retail investors withdrawing 51.44 million yuan [3] - Yunnan Baiyao (000538) had a net inflow of 52.53 million yuan from institutional investors, but retail investors withdrew 56.48 million yuan [3]

Core Viewpoint - Jilin Aodong's stock price has shown significant growth this year, with a 23.47% increase, and the company is actively involved in various sectors including traditional Chinese medicine and health products [1][2]. Financial Performance - For the first half of 2025, Jilin Aodong reported a revenue of 1.126 billion yuan, a year-on-year decrease of 20.21%, while the net profit attributable to shareholders was 1.282 billion yuan, reflecting a year-on-year increase of 138.44% [2]. - Cumulative cash dividends since the company's A-share listing amount to 4.664 billion yuan, with 1.881 billion yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Jilin Aodong was 66,000, a decrease of 1.60% from the previous period, with an average of 18,059 circulating shares per shareholder, an increase of 1.62% [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 4.6149 million shares to 15.0138 million shares, and Southern CSI 500 ETF, which increased its holdings by 1.9148 million shares to 14.2479 million shares [3].

Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. has announced its 2025 interim cash dividend distribution plan, which includes a total cash dividend of 234,476,317.40 yuan, distributing 2.00 yuan per 10 shares to shareholders [2][3][10]. Summary by Sections Dividend Distribution Plan - The cash dividend distribution plan was approved at the company's first extraordinary general meeting on September 19, 2025, with a total share capital of 1,195,895,387 shares, excluding 23,513,800 shares held in the company's repurchase account [3][4]. - The actual cash dividend amount is calculated based on the adjusted total shares eligible for distribution, resulting in a cash dividend of 2.00 yuan per 10 shares, amounting to a total of 234,476,317.40 yuan [2][3][10]. Shareholder Eligibility - The dividend distribution is applicable to all shareholders registered with China Securities Depository and Clearing Corporation Limited, Shenzhen Branch, as of the close of trading on October 21, 2025 [8][11]. Payment Method - Cash dividends will be distributed on October 22, 2025, through the shareholders' securities companies or other custodial institutions [9][11]. - The company will bear all legal responsibilities if there are any discrepancies in the cash dividend distribution due to changes in shareholders' account holdings during the application period [9]. Taxation Details - The cash dividend will be subject to different tax rates based on the type of shares held, with specific provisions for Hong Kong investors and domestic investors [7][8].

（文章来源：证券日报） 证券日报网讯 10月13日晚间，吉林敖东发布公告称，公司2025年半年度利润分配方案为：以公司现有 总股本1，195，895，387股扣除公司股票回购专用证券账户上的股份23，513，800股后的1，172， 381，587股为基数，向全体股东每10股派2.00元人民币现金（含税）。股权登记日为2025年10月21日， 除权除息日为2025年10月22日。 ...

Group 1 - The company Jilin Aodong (SZ 000623) announced a profit distribution plan, proposing a cash dividend of 2 yuan per 10 shares, amounting to approximately 234 million yuan in total [1] - The total share capital for the distribution is approximately 1.172 billion shares after deducting about 23.51 million shares held in the company's stock repurchase account [1] - The ex-dividend date is set for October 22, 2025, with the record date on October 21, 2025 [1] Group 2 - For the first half of 2025, the company's revenue composition is as follows: 73.63% from the pharmaceutical industry, 16.59% from wholesale and retail of chain pharmacies, 7.39% from food, 1.76% from other industries, and 0.62% from other businesses [1] - As of the report date, Jilin Aodong's market capitalization stands at 24.6 billion yuan [1]

证券代码：000623 证券简称：吉林敖东 公告编号：2025-054 吉林敖东药业集团股份有限公司 2025年中期分红派息实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1.吉林敖东药业集团股份有限公司（以下简称"公司"）回购专用证券账户 中的股份不参与2025年中期权益分派，公司本次实际现金分红的总金额=实际参 与分配的总股本×分配比例，即234,476,317.40元=1,172,381,587股×0.20元/ 股。 2.本次权益分派实施后，根据股票市值不变原则，实施权益分派前后公司总 股本保持不变，现金分红总额分摊到每一股的比例将减小，因此，本次权益分派 实施后除权除息价格计算时，按股权登记日的总股本折算的每10股现金红利=实 际 现 金 分 红 总 金 额 ÷ 股 权 登 记 日 的 总 股 本 × 10=234,476,317.40÷1,195,895,387×10=1.960675元，即：本次权益分派实施 后的除权除息价格=股权登记日收盘价-0.1960675元/股。 公司2025年半年度利润分配方案已获公司于2025年9月 ...